UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 78

Sortiert nach

Improvement of EGFR Testing over the Last Decade and Impact of Delaying TKI Initiation

Current oncology (Toronto), 2021-02, Vol.28 (2), p.1045-1055

2021

Volltextzugriff (PDF)

Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC

Current oncology (Toronto), 2021-01, Vol.28 (1), p.593-605

2021

Volltextzugriff (PDF)

Adult Medulloblastoma Demographic, Tumor and Treatment Impact since 2006: A Canadian University Experience

Current oncology (Toronto), 2021-08, Vol.28 (4), p.3104-3114

2021

Volltextzugriff (PDF)

A phase I/II study of pembrolizumab in combination with nab-paclitaxel in patients with unresectable stage III or stage IV non small-cell lung carcinoma (NSCLC)

Cancer treatment and research communications, 2021, Vol.28, p.100421-100421, Article 100421

2021

Volltextzugriff (PDF)

Stereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC)

Clinical and translational radiation oncology, 2022-03, Vol.33, p.115-119

2022

Volltextzugriff (PDF)

The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy

Cancer treatment and research communications, 2023, Vol.37, p.100767-100767, Article 100767

2023

Volltextzugriff (PDF)

Economic Analysis of NCIC CTG JBR.10: A Randomized Trial of Adjuvant Vinorelbine Plus Cisplatin Compared With Observation in Early Stage Non–Small-Cell Lung Cancer—A Report of the Working Group on Economic Analysis, and the Lung Disease Site Group, National Cancer Institute of Canada Clinical Trials Group

Journal of clinical oncology, 2007-06, Vol.25 (16), p.2256-2261

2007

Volltextzugriff (PDF)

Prognosis of thoracic radiation-induced metastatic NSCLC

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e21095-e21095

2018

Volltextzugriff (PDF)

Prognosis in young women under 40 with brain metastasis from breast cancer

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.1091-1091

2018

Volltextzugriff (PDF)

Impact of different risk factors on survival of malignant pleural mesothelioma

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e20561-e20561

2018

Volltextzugriff (PDF)

QOL-25. IMPACTS OF IMPLEMENTING A PROSPECTIVE TREATMENT AND SURVEILLANCE PROTOCOL FOR THE MANAGEMENT OF NF2-ASSOCIATED VESTIBULAR SCHWANNOMAS ON TUMOR GROWTH, HEARING OUTCOMES, AND QUALITY OF LIFE

Neuro-oncology (Charlottesville, Va.), 2022-11, Vol.24 (Supplement_7), p.vii246-vii246

2022

Volltextzugriff (PDF)

Use of positron emission tomography-computed tomography (PET-CT) scan in cancer patients: A single Canadian academic oncology center experience

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e18691-e18691

2023

Volltextzugriff (PDF)

Reflex testing for RAS and BRAF mutations in metastatic colorectal cancer: A single Canadian academic oncology center experience

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.86-86

2023

Volltextzugriff (PDF)

High intensity interval training safety and efficacy in patients with advanced NSCLC receiving systemic treatment: Results of a prospective trial

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.12054-12054

2021

Volltextzugriff (PDF)

Survival impact of aggressive treatment on patients with oligometastatic non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e20669-e20669

2017

Volltextzugriff (PDF)

Does blood sugar impact on metastatic non-small cell lung cancer (NSCLC) outcome?

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e20579-e20579

2017

Volltextzugriff (PDF)

Adjuvant chemotherapy outcome in unselected single-center non-small cell lung cancer (NSCLC) population

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e20089-e20089

2017

Volltextzugriff (PDF)

IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial

Journal of clinical oncology, 2023-06, Vol.41 (17_suppl), p.LBA8505-LBA8505

2023

Volltextzugriff (PDF)

Prognostic impact of paraneoplastic syndromes in patients with small cell lung cancer, real-world data

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e20082-e20082

2019

Volltextzugriff (PDF)

The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and the influence of the NLR in NSCLC patients treated with immunotherapy

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e21010-e21010

2021

Volltextzugriff (PDF)

Mutations in NSCLC and their link with lung cancer-associated thrombosis: A case-control study

Thrombosis research, 2014-01, Vol.133 (1), p.48-51

2014

Volltextzugriff (PDF)

Prognosis in young women less than 40 years of age with brain metastasis from breast cancer

Current oncology (Toronto), 2020-02, Vol.27 (1), p.39-45

2020

Volltextzugriff (PDF)

Association between immune-related adverse events and microbiome composition in patients with advanced non–small cell lung cancer treated with immunotherapy

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.9036-9036

2022

Volltextzugriff (PDF)

Tyrosine kinase inhibitor (TKI) cessation in advanced non-small-cell lung cancer (aNSCLC) for improved detection of EGFR-mutated (EGFRm) circulating tumor DNA (ctDNA)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e21064-e21064

2018

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(72)
Mit Volltextzugriff
(75)

Publikationsform

Artikel
(78)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(32)
Life Sciences & Biomedicine
(30)
Humans
(23)
Oncology
(16)
Female
(13)
Male
(13)
Middle Aged
(11)
Aged
(8)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(7)
Immunotherapy
(6)
Lung Neoplasms - Drug Therapy
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)
Lung Cancer
(5)
Patients
(5)
Retrospective Studies
(5)
Carcinoma, Non-Small-Cell Lung - Genetics
(4)
Lung Neoplasms - Genetics
(4)
Lung Neoplasms - Pathology
(4)
Monoclonal Antibodies
(4)
Neoplasm Staging
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Improvement of EGFR Testing over the Last Decade and Impact of Delaying TKI Initiation

Survival Impact of Aggressive Treatment and PD-L1 Expression in Oligometastatic NSCLC

Adult Medulloblastoma Demographic, Tumor and Treatment Impact since 2006: A Canadian University Experience

A phase I/II study of pembrolizumab in combination with nab-paclitaxel in patients with unresectable stage III or stage IV non small-cell lung carcinoma (NSCLC)

Stereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC)

The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy

Prognosis of thoracic radiation-induced metastatic NSCLC

Prognosis in young women under 40 with brain metastasis from breast cancer

Impact of different risk factors on survival of malignant pleural mesothelioma

QOL-25. IMPACTS OF IMPLEMENTING A PROSPECTIVE TREATMENT AND SURVEILLANCE PROTOCOL FOR THE MANAGEMENT OF NF2-ASSOCIATED VESTIBULAR SCHWANNOMAS ON TUMOR GROWTH, HEARING OUTCOMES, AND QUALITY OF LIFE

Use of positron emission tomography-computed tomography (PET-CT) scan in cancer patients: A single Canadian academic oncology center experience

Reflex testing for RAS and BRAF mutations in metastatic colorectal cancer: A single Canadian academic oncology center experience

Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real-world multicentre study

High intensity interval training safety and efficacy in patients with advanced NSCLC receiving systemic treatment: Results of a prospective trial

Survival impact of aggressive treatment on patients with oligometastatic non-small cell lung cancer (NSCLC)

Does blood sugar impact on metastatic non-small cell lung cancer (NSCLC) outcome?

Adjuvant chemotherapy outcome in unselected single-center non-small cell lung cancer (NSCLC) population

IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): A CCTG, NCIN, and IFCT trial

Prognostic impact of paraneoplastic syndromes in patients with small cell lung cancer, real-world data

The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and the influence of the NLR in NSCLC patients treated with immunotherapy

Mutations in NSCLC and their link with lung cancer-associated thrombosis: A case-control study

Prognosis in young women less than 40 years of age with brain metastasis from breast cancer

Association between immune-related adverse events and microbiome composition in patients with advanced non–small cell lung cancer treated with immunotherapy

Tyrosine kinase inhibitor (TKI) cessation in advanced non-small-cell lung cancer (aNSCLC) for improved detection of EGFR-mutated (EGFRm) circulating tumor DNA (ctDNA)

Suchergebnisse filtern